FDA approves AFX2 Bifurcated Endograft System for abdominal aortic aneurysms- Endologix

Endologix has received FDA approval for the AFX2 Bifurcated Endograft System for the treatment of abdominal aortic aneurysms (AAA). AFX2 reduces procedure steps for the delivery and deployment of the bifurcated endograft. The new device also facilitates percutaneous EVAR by providing low profile contralateral access through a 7F introducer. These improvements combine to make an integrated new EVAR (endovascular aneurysm repair) system.